"uuid:ID","versionIdentifier","rationale","instanceType","id"
"396cde51-2520-4e66-a043-ffd5e371741c","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","StudyVersion_1"
